SCHEMBL4486193

SCHEMBL4486193

CC(C)NC(=O)c1c2c(c(O)c(=O)n1C)C(=O)N(Cc1ccc(F)cc1)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
LMNA P02545 6/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
HTT P42858 4/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
POLB P06746 1/20 0.39
AKR1B1 P15121 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
PTGER4 P35408 1/20 0.38
THRB P10828 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487792 0.87 THRB (0.46) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4484527 0.86 CNR2 (0.46)
SCHEMBL13672778 0.86 AKR1B1 (0.43) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4480856 0.86 CNR1 (0.44)
SCHEMBL4487954 0.85 ALOX5 (0.45) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4481908 0.85 AKR1B1 (0.38) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4495602 0.83 AKR1B1 (0.40) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL13672777 0.83 AKR1B1 (0.41) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4489237 0.83 AKR1B1 (0.37) TP53LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4473972 0.82 AKR1B1 (0.41) LMNASMN1; SMN2HTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H TP53 1359/4885LMNA 4273/4885SMN1; SMN2 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.